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A B S T R A C T
Alzheimer’s Disease (AD) has become a major health issue in recent decades, and there is now growing interest in
amnestic mild cognitive impairment (aMCI), an intermediate stage between healthy aging and dementia, usually
AD. Event-related brain potential (ERP) studies have sometimes failed to detect differences between aMCI and
control participants in the Go-P3 (or P3b, related to target classification processes in a variety of tasks) and
NoGo-P3 (related to response inhibition processes, mainly in Go/NoGo tasks) ERP components. The aim of the
present study was to evaluate whether the age factor, which is not usually taken into account in ERP studies,
modulates group differences in these components. With this aim, we divided two groups of volunteer partici-
pants, 34 subjects with aMCI (51–87 years) and 31 controls (52–86 years), into two age subgroups: 69 years or
less and 70 years or more. We recorded brain activity while the participants performed a distraction-attention
auditory-visual (AV) task. Task performance was poorer in the older than in the younger group, and aMCI
participants produced fewer correct responses than the matched controls; but no interactions of the age and
group factors on performance were found. On the other hand, Go-P3 and NoGo-N2 latencies were longer in aMCI
participants than in controls only in the younger subgroup. Thus, the younger aMCI participants categorized the
Go stimuli in working memory and processed the NoGo stimuli (which required response inhibition) slower than
the corresponding controls. Finally, the combination of the number of hits, Go-P3 latency and NoGo-N2 latency
yielded acceptable sensitivity and specificity scores (0.70 and 0.92, respectively) as regards distinguishing aMCI
participants aged 69 years or less from the age-matched controls. The findings indicate age should be taken into
account in the search for aMCI biomarkers.
1. Introduction
The world’s population is aging, owing to decreased birth rates and
increased life expectancy (Park & Reuter-Lorenz, 2009). The ac-
celerated increase in aging is accompanied by an increase in the pre-
valence of neurodegenerative diseases.
Alzheimer’s Disease (AD) is the most common form of dementia and
is becoming increasingly more prevalent (Andreasen & Blennow, 2005;
Bennys, Rondouin, Benattar, Gabelle, & Touchon, 2011), at great cost to
affected individuals and their families and to society as a whole (Park &
Reuter-Lorenz, 2009). The prevalence and incidence rates of AD in-
creases exponentially with age, with the most notable rise from 70 years
on, as the late-onset form of AD accounts for more of the 95% of af-
fected (Reitz, Brayne, & Mayeux, 2011).
However, most AD patients experience some memory decline before
reaching the clinical threshold for the diagnosis of AD (Petersen et al.,
2001). The state in which there is greater memory loss than expected
for normal aging, but which does not affect daily living and does not
meet the criteria for AD, is termed amnestic Mild Cognitive Impairment
(aMCI; Petersen et al., 2001, 2009). Individuals with aMCI show an
increased risk of developing AD relative to healthy aging: longitudinal
studies have revealed that aMCI patients have an 80% chance of de-
veloping AD within 6 years of diagnosis (Petersen et al., 2001, 2009,
1999). The prevalence of MCI at present is difficult to calculate, as it
depends on the precise diagnostic criteria (Ward, Arrighi, Michels, &
Cedarbaum, 2012). Despite this, as AD increases doubles every 5 years
after age 65 (Jones, Bruns, & Petersen, 2017), it is worthy to evaluate
adults with aMCI from several years before that age.
Characterization of aMCI is important to enable correct diagnosis
and prognosis, thus increasing the probability of clinical intervention
before brain damage becomes irreversible (Bredesen, 2014). The search
for aMCI markers has therefore received a great deal of attention in the
last two decades. Useful biomarkers should be able to detect the neu-
ropathology and must be validated in neuropathologically confirmed
cases. In addition, biomarkers should also be precise, reliable, non-in-
vasive, simple to obtain and inexpensive (Thies, Truschke, Morrison-
Bogorad, & Hodes, 1998). Although several aMCI biomarkers have been
proposed (Albert et al., 2011), they are expensive (e.g. functional
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magnetic resonance imaging) and/or invasive (e.g. positron emission
tomography, cerebrospinal fluid measures) and have either not been
validated (Jack et al., 2011) or show limited sensitivity and specificity
(DeKosky & Marek, 2003; Reitz & Mayeux, 2014; Reitz et al., 2011).
The event-related brain potentials (ERP) technique is a suitable tool
for use in the search for biomarkers, as it is non-invasive and relatively
inexpensive, and has already shown to be useful in the search for bio-
markers of aMCI and AD (e.g. Cespón, Galdo-Álvarez, & Díaz, 2013;
Cespón, Galdo-Álvarez, & Díaz, 2015; Cespón, Galdo-Álvarez, Pereiro,
& Díaz, 2015; Correa-Jaraba, Lindín, & Díaz, 2018; Lindín, Correa,
Zurrón, & Díaz, 2013; for reviews, see Jackson & Snyder, 2008; Vecchio
& Määttä, 2011).
In previous studies involving the search for biomarkers of aMCI, we
used the ERP technique to record the brain activity of participants while
they performed a distraction-attention auditory-visual (AV) task (Cid-
Fernández, Lindín, & Díaz, 2017; Cid-Fernández, Lindín, & Díaz, 2017;
Cid-Fernández, Lindín, & Díaz, 2014; Lindín et al., 2013). In this task,
participants are presented with pairs of auditory-visual stimuli, and
they are asked to attend to the visual stimuli (making a Go/NoGo task)
and to ignore the auditory stimuli (consisting of a passive oddball task
with three stimuli: standard, deviant and novel). The following ERP
components associated with the processing of visual stimuli (preceded
by standard auditory stimuli) were identified and evaluated: (1) N2b
(Go-N2) and P3b (Go-P3), in response to Go visual stimuli, and (2)
NoGo-N2 and NoGo-P3, in response to NoGo visual stimuli. The Go-N2
and NoGo-N2 amplitudes were smaller in aMCI than in control parti-
cipants, indicating deficits in the evaluation of target stimuli in working
memory (WM) and in response inhibition processes, respectively, in
participants with aMCI. No differences were observed between the
groups in relation to the Go- and NoGo-P3 components, or in Go- and
NoGo-N2 latencies (Cid-Fernández et al., 2014b, 2017a; Mudar et al.,
2016).
Go-P3 (or P3b) is a widely studied ERP component, typically max-
imal at parietal electrodes in young adults, with latencies of
300–700 ms after stimulus presentation. The stimuli that elicit this ERP
component are attended stimuli that require a response, e.g. the target
stimuli of an oddball task, or the Go stimuli of a Go/NoGo task. Go-P3 is
typically interpreted as a correlate of context updating (when a target
stimulus is presented) or of stimulus classification in working memory
(Coles & Rugg, 1996; Donchin & Coles, 1988; Kutas, Iragui, & Hillyard,
1994). Most studies using an oddball task have reported longer P3b
latencies in aMCI patients than in healthy controls (e. g. Bennys, Portet,
Touchon, & Rondouin, 2007; Lai, Lin, Liou, & Liu, 2010; Li et al., 2010;
Papadaniil et al., 2016; Papaliagkas, Kimiskidis, Tsolaki, &
Anogianakis, 2008; Parra, Ascencio, Urquina, Manes, & Ibáñez, 2012),
although other studies did not observe any differences (Papaliagkas,
Kimiskidis, Tsolaki, & Anogianakis, 2011). Regarding the P3b ampli-
tude, most studies did not reveal differences between groups (e. g.
Bennys et al., 2007; Golob, Irimajiri, & Starr, 2007; Lai et al., 2010;
Papadaniil et al., 2016; Papaliagkas et al., 2008, 2011), although in
some studies this parameter was significantly smaller in aMCI patients
than in healthy controls (Li et al., 2010; Parra et al., 2012).
On the other hand, the NoGo-P3 component peaks around the
300–500 latency window at central electrodes after presentation of a
NoGo stimulus that requires a prepotent response to be withheld. This
has been interpreted as an index of response inhibition processes
(Bokura, Yamaguchi, & Kobayashi, 2001; Jackson, Jackson, & Roberts,
1999; Nakata, Sakamoto, Inui, Hoshiyama, & Kakigi, 2009). Studies
evaluating the NoGo-P3 parameters have generally not found any dif-
ferences between MCI participants and controls (2017a, Cid-Fernández,
Lindín, & Díaz, 2014; Mudar et al., 2016). However, López Zunini et al.
(2016) observed smaller NoGo-P3 amplitudes in aMCI than in control
participants, interpreting this result as an indicator of impaired motor
response inhibition processes in aMCI.
In two previous ERP studies carried out in our laboratory, differ-
ences between aMCI participants and healthy controls were observed,
but only when the sample was split into different age groups. Lindín
et al. (2013) used the AV task and analyzed the mismatch negativity
(MMN), a component related to automatic and pre-attentive processing
of stimuli (Näätänen, Paavilainen, Rinne, & Alho, 2007). The MMN
amplitude was smaller in the aMCI than in the control participants, but
only in the group aged 50–64 years and not in older participants (Lindín
et al., 2013). In addition, in a Stroop task study, Ramos-Goicoa, Galdo-
Álvarez, Díaz, and Zurrón, (2016) observed longer P3b latency in aMCI
than in healthy participants, but only in the younger subgroup (64 years
old or less). Altogether these results show that some important effects
(and potential aMCI biomarkers) may be masked when the age factor is
not taken into account in the analyses. Indeed, Ramos-Goicoa et al.
(2016) suggested that the age factor may have some influence in the
mixed results found in the literature regarding P3b latency.
In line with this observation, the age ranges of the mentioned stu-
dies differ considerably: while the participants of the study that ob-
served group differences in P3b latency are the youngest (younger
subgroups age range = 51–64 years old; Ramos-Goicoa et al., 2016)
those of studies that did not find such differences were quite (Mudar
et al., 2016; age range = 54–86 years old; aMCI mean age = 68.5 years
old; control mean age = 65.4 years old) or much (López Zunini et al.,
2016; aMCI mean age = 75.6 years old; control mean age = 72.4 years
old) older. On the other hand, only the study that used the eldest
sample was able to observe differences regarding P3b amplitude, as this
parameter was larger in the control than in the aMCI group (López
Zunini et al., 2016).
In the present study, we used the AV task to evaluate (1) possible
differences between control (healthy) participants and aMCI partici-
pants in task performance (reaction time -RT- and number of correct
responses), in the Go-N2 and -P3 ERP components (in response to visual
stimuli that required a response), and in the NoGo-N2 and -P3 ERP
components (in response to visual stimuli that required to withhold a
prepotent response); and (2) whether these differences are modulated
by age. For this purpose, two age subgroups were established for sta-
tistical comparison: participants aged 69 years or less and participants
70 years or more. We tested whether the Age factor interacts with the
Group factor (aMCI vs controls), to clarify whether important group
effects on the parameters of the aforementioned ERP components may
be overlooked.
According to previous reports, we expected to find differences be-
tween groups in the behavioural measures, with poorer performance in
the aMCI than in the control participants (longer RT and fewer correct
responses). By contrast, we did not expect to find any general group
differences in the Go- and NoGo-P3 latencies, and only expected to find
longer Go-P3 latencies in the aMCI than in the control participants in
the younger subgroups, in accordance with Ramos-Goicoa et al. (2016).
In addition, we did not expect to find group differences for the Go-P3
amplitude, in the global sample or in either of the age subgroups. Fi-
nally, we were also expecting to find some age-dependent differences
between groups for the Go-N2 (or N2b) and NoGo-N2 latencies, as (1)
in previous studies using the A-V task we failed to observe any group
differences regarding these parameters, and (2) it seems that there are
significant changes in the N200 subcomponents in MCI adults com-
pared to healthy adults across studies, despite some contradictions
between results (for a review see Howe, 2014).
2. Materials and methods
2.1. Participants
Sixty-five volunteers were recruited from Primary Care Health
Centers in Santiago de Compostela, Galicia (Spain), after being referred
to our research group by their general practitioners (GPs). The parti-
cipants had no history of clinical stroke, traumatic brain injury, motor-
sensory deficits or alcohol or drug abuse/dependence, and they were
not diagnosed with any significant medical or psychiatric illnesses.
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Each participant then underwent the following neuropsychological
tests: 1) the Spanish version of the Mini-Mental State Examination
(MMSE; Lobo et al., 1999); 2) the Spanish version of the Californian
Verbal Learning Test (CVLT; Benedet Álvarez & Alexandre, 1998),
which assesses short-delay free recall, short-delay recall with semantic
cues, and long-delay free recall; 3) the Spanish version of the Cam-
bridge Cognitive Examination (CAMCOG-R), which assesses deteriora-
tion in specific domains, such as language, attention-calculation, praxis,
perception and executive functioning (Huppert et al., 1996); and (4) the
Spanish version of the Lawton-Brody Instrumental Activities of Daily
Living (IADL) scale (Vergara et al., 2012).
Participants were classified into two groups: Control (31 subjects,
aged between 52 and 86 years, with normal cognitive functioning) and
aMCI (34 subjects aged between 51 and 87 years). The aMCI partici-
pants met the general criteria for MCI outlined by Albert et al. (2011)
and the criteria for aMCI proposed by Petersen (2004). Thus, all aMCI
participants fulfilled the following criteria: 1) memory complaints
corroborated by an informant; 2) performance of less than 1.5 SDs
below age norms in the CVLT; 3) no significant impact on activities of
daily living; and 4) no dementia. For a more extensive description of the
global samples, see Juncos-Rabadán, Facal, Lojo-Seoane, and Pereiro
(2013). The aMCI and control participants were matched according to
age and level of education.
In order to evaluate whether the age factor modulates the differ-
ences between the groups, two subgroups were established in each
group: 69 years or less and 70 years or more. In each age subgroup,
aMCI and control participants were also matched according to age and
level of education. The demographic and neuropsychological measures
of the participants are summarized in Table 1, together with the dif-
ferences between groups, calculated by the corresponding analysis.
To control for the effects of depression, volunteers with scores of
more than 10 in depression screening (Geriatric Depression Scale;
Yesavage et al., 1983) were not included in the study. All participants
had normal audition and normal or corrected-to-normal vision. All
were right-handed, as assessed by the Edinburgh inventory (Oldfield,
1971). Right after the neuropsychological evaluation, participants un-
derwent the psychophysiological evaluation.
In addition, all participants gave their written informed consent
prior to taking part in the study. The research project was approved by
the Galician Clinical Research Ethics Committee (Xunta de Galicia,
Spain). The study was performed in accordance with the ethical stan-
dards established in the 1964 Declaration of Helsinki (Lynöe, Sandlund,
Dahlqvist, & Jacobsson, 1991).
2.2. Procedure
The distraction-attention auditory-visual task was adapted from
Escera, Alho, Winkler, and Näätänen, (1998). Participants were pre-
sented with 500 pairs of auditory-visual (A-V) stimuli. Each pair of
stimuli consisted of a visual stimulus (200 ms duration) preceded by an
auditory stimulus (150 ms duration), separated by an interval of 300 ms
(SOA). Each pair of stimuli was separated by an interval of 2 s. Parti-
cipants were asked to attend to the visual stimuli and to ignore the
auditory stimuli. They should respond pressing one button with one
hand if the visual stimulus was a letter, another button with the other
hand if it was a number (33% each; Go stimuli), and withhold their
responses if it was a triangle (34%; NoGo stimuli). The task procedure is
further explained in Cid-Fernández et al. (2017b; see Fig. 1; and
2017b).
2.3. EEG recording
The EEG was recorded via 49 electrodes placed in an elastic cap
(Easycap, GmbH), according to the International 10-10 System. All
electrodes were referenced to an electrode attached to the tip of the
nose, and an electrode positioned at Fpz served as ground. The hor-
izontal electrooculogram (EOG) was recorded via two electrodes placed
at the outer canthi of both eyes, whereas the vertical EOG was recorded
via two electrodes placed supra and infraorbitally to the right eye. The
EEG was continuously digitized at a rate of 500 Hz (bandpass
0.01–100 Hz), and the electrode impedance was maintained below 10 k
Ω.
Once the signal was stored, it was passed through a digital
0.1–30 Hz (24 dB/octave slope) bandpass filter, and ocular artefacts
were corrected using the Gratton, Coles & Donchin method (Gratton,
Coles, & Donchin, 1983).
With the aim of evaluating the ERP components of interest (Go-N2,
NoGo-N2, Go-P3 and NoGo-P3 components), the EEG was segmented
by extraction of auditory stimulus-locked epochs of 1450 ms (150 ms
pre-auditory stimulus). The epochs composed by the standard auditory-
target visual pairs with correct responses were evaluated. All epochs
were corrected to the mean voltage of the first 150 ms of each epoch,
and segments exceeding ± 100 μV were automatically rejected. The
epochs were then averaged separately for the Go and NoGo trials (Go
and NoGo conditions, respectively), and a minimum of 38 artefact-free
epochs were averaged for each condition.
Table 1
Mean values and standard deviations (in parentheses) of the demographical and neuropsychological measures considered.
C aMCI p ≤ * C ≤ 69 y.o. aMCI ≤ 69 y.o. p ≤ * C ≥ 70 y.o. aMCI ≥ 70 y.o. p ≤ *
N = 31 N = 34 N = 13 N = 17 N = 18 N = 17
Age 69.6 (9.5) 69.9 (9.1) .896 60.1 (5.8) 62.7 (5.6) .228 76.4 (4.0) 77.1 (5.4) .675
Years of education 9.1 (5.0) 9.1 (4.5) .984 9.8 (5.5) 9.7 (4.5) .947 8.6 (4.6) 8.5 (4.5) .987
Sex (Women/Men) 22/9 19/15 9/4 8/9 13/5 11/6
MMSE 28.0 (1.8) 25.7 (2.5) .001 28.6 (1.2) 26.3 (2.0) .001 27.6 (2.1) 25.0 (2.8) .004
CVLT (short-delay free recall) 8.9 (3.1) 3.7 (1.9) .001 11.2 (2.5) 4.7 (1.4) .001 7.2 (2.3) 2.6 (1.7) .001
CVLT (short-delay cued recall) 10.4 (3.2) 5.5 (2.2) .001 12.6 (1.9) 6.4 (1.7) .001 8.9 (3.1) 4.5 (2.4) .001
CVLT (long-delay free recall) 9.8 (3.5) 4.1 (3.1) .001 12.5 (2.9) 5.3 (2.7) .001 8.2 (3.0) 2.9 (3.0) .001
CVLT (long-delay cued recall) 10.6 (3.3) 5.7 (2.7) .001 12.5 (2.1) 6.5 (1.9) .001 9.2 (3.4) 5.0 (3.2) .001
CAMCOG-R (Orientation) 9.4 (0.9) 9.1 (1.0) .146 9.9 (0.4) 9.4 (0.7) .056 9.1 (1.1) 8.7 (1.2) .303
CAMCOG-R (Language) 24.9 (2.1) 24.3 (2.9) .293 25.8 (2.1) 24.7 (2.4) .219 24.3 (1.9) 23.8 (3.3) .579
CAMCOG-R (Attention and Calculation) 7.4 (1.5) 6.4 (2.3) .036 7.6 (1.6) 6.6 (2.3) .177 7.2 (1.4) 6.1 (2.3) .097
CAMCOG-R (Praxis) 10.9 (1.3) 9.9 (2.6) .058 11.1 (1.3) 9.8 (2.7) .136 10.7 (1.3) 9.9 (2.5) .250
CAMCOG-R (Perception) 6.3 (1.5) 6.2 (1.5) .888 6.5 (1.7) 6.5 (1.4) .987 6.1 (1.4) 5.9 (1.6) .737
CAMCOG-R (Executive function) 15.9 (5.2) 14.6 (4.1) .249 18.6 (6.0) 15.5 (3.9) .092 13.9 (3.6) 13.7 (4.2) .823
C: control group; aMCI: amnestic MCI group; y.o.: years old; MMSE: Mini-Mental State Examination; CVLT: California Verbal Learning Test; CAMCOG-R: Cambridge
Cognitive Examination.
* ANOVA (Group), signification level < 0.05.
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2.4. Data analysis
Reaction times (RTs, between the onset of the visual stimulus and
pressing the key) for correct responses and the number of correct re-
sponses (Hits) were evaluated in the Go condition.
The Go-N2 (in the 250–430 ms interval) and the Go-P3 (in the
450–750 ms interval) components (after the Go visual stimulus), and
the NoGo-N2 (in the 200–360 ms interval) and the NoGo-P3 (in the
400–650 ms interval) components (after the NoGo visual stimulus)
were also evaluated. The peak amplitudes (in microvolts) and latencies
(in milliseconds) of the Go- and NoGo-N2 and -P3 components were
evaluated at the midline electrode where the amplitude was maximal
(Pz for Go-P3, Cz for Go-N2, NoGo-N2 and NoGo-P3).
2.5. Statistical analysis
Two-factor analysis of variance (ANOVA), with the between-subject
factors Group (two levels: Control, aMCI) and Age (two levels: 69 or less
years old and 70 or more years old), was applied to the RTs, Hits and
amplitudes and latencies of the Go-N2 and -P3 and the NoGo-N2 and
-P3 components. Whenever the ANOVAs revealed significant effects due
to the factors or their interactions, post hoc comparisons of the mean
values (adjusted to Bonferroni correction) were conducted. Differences
were considered significant at p ≤ 0.05.
Finally, receiver operating characteristic (ROC) curves were con-
structed for those ERP and behavioral parameters in which the Group
factor exerted a significant main effect or interaction. These parameters
Fig. 1. Grand-average event-related brain potential waveforms for the age subgroups in the control (blue/light grey line) and aMCI (orange/dark grey line) groups,
for each condition (Go: upper panel; NoGo: lower panel) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article).
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were also combined by constructing a binary logistic regression model,
with the parameters included as the explanatory variables (covariates)
and the group of interest as the dependent variable. The predicted
probabilities were saved as a new variable and ROC curves were
computed. An area under the curve (AUC) of 1.0 corresponds to a
perfect prediction, whereas a value of 0.5 indicates a useless model.
3. Results
The RTs, number of hits, and amplitudes and latencies of the Go-
and NoGo-N2, and Go- and NoGo-P3 components are summarized in
Table 2, and the ERP waveforms evaluated are depicted in Fig. 1.
3.1. Behavioural measures
The two factor ANOVA (Group x Age) applied to the RTs revealed a
significant effect of the Age factor (F (1, 59) = 4.2, p = .045), as this
parameter was significantly longer in the older (70 or more years old)
than in the younger (69 or less years old) participants (see Table 2).
There were no other significant effects or interactions regarding the
RTs.
The two factor ANOVA (Group x Age) applied to the number of hits
also revealed a significant effect of the Age factor (F (1, 59) = 8.6,
p = .005), as this parameter was significantly smaller in the older than
in the younger participants (see Table 2). In addition, a marginally
significant effect of the Group factor was observed (F (1, 59) = 3.4,
p = .07), as this parameter was smaller in the aMCI than in the Control
group (see Table 2). No significant interaction of the factors was ob-
served.
3.2. ERP components
3.2.1. Go-N2 and NoGo-N2
The two-factor ANOVAs (Group × Age) did not show any sig-
nificant main effects or interactions of the factors for the Go-N2 am-
plitude and latency or the NoGo-N2 amplitude at the Cz electrode lo-
cation.
The two-factor ANOVA (Group × Age) applied to the NoGo-N2
latency at Cz showed a significant effect of the Group × Age interaction
(F (1, 50) = 6.1, p = .017), as this parameter was significantly longer
(p = .004) in the aMCI than in the control participants, but only in the
younger subgroup (69 or less years old), and significantly longer
(p = .039) in the elder controls (70 or more years old) than in the
younger controls (69 or less years old; see Fig. 1).
3.2.2. Go-P3 and NoGo-P3
The two factor ANOVAs (Group × Age) applied to the Go-P3 am-
plitude at Pz, did not show any significant main effects or interactions.
The two factor ANOVA (Group × Age) applied to the Go-P3 latency
at Pz revealed a significant effect of the Group × Age interaction (F (1,
54) = 4.5, p = .039), as this parameter was significantly longer in the
aMCI than in the control participants, but only in the younger subgroup
(≤ 69 years old; p = .049; see Fig. 1).
The two factor ANOVAs (Group × Age) applied to the NoGo-P3
amplitude and latency at Cz did not show any significant main effects or
interactions of the factors.
3.3. ROC curves
The number of hits discriminated groups (aMCI versus controls) with
sensitivity and specificity scores of 0.59 and 0.62, respectively
(AUC = .68). In addition, the Go-P3 latency (at Pz) showed sensitivity
and specificity scores of 0.65 and 0.66, respectively, for distinguishing
control and aMCI participants aged ≤ 69 years (AUC = 0.71). For the
same comparison (control versus aMCI in the younger subgroup), the
NoGo-N2 latency (at Cz) showed sensitivity and specificity scores of
0.60 and 0.67, respectively.
The number of hits and Go-P3 latency at Pz were then combined
with the aim of distinguishing aMCI participants aged ≤ 69 years from
their control counterparts, yielding a sensitivity score of 0.82 and a
specificity score of 0.75 (AUC = 0.79). For the same comparison, the
combination of NoGo-N2 latency (at Cz) and Go-P3 latency (at Pz)
yielded sensitivity and specificity scores of 0.70 and 0.67, respectively,
while the combination of NoGo-N2 latency at Cz and the number of hits
yielded sensitivity and specificity scores of 0.80 and 0.75, respectively.
Finally, the three parameters (number of hits, NoGo-N2 latency at
Cz and Go-P3 latency at Pz) were combined with the aim of distin-
guishing aMCI from control participants of 69 years-old or less, ob-
taining a sensitivity score of 0.70 and a specificity score of 0.92.
4. Discussion
The RT was significantly longer and the number of hits significantly
lower in the older (≥ 70 years old) than in the younger (≤ 69 years
old) participants. In addition, the number of hits was lower in the aMCI
than in the Control group (although this effect was only marginally
significant). The Go-P3 (or P3b) and the NoGo-N2 latencies were sig-
nificantly longer in the aMCI than in the control participants, but only
in the younger subgroup (≤ 69 years old). In addition, the NoGo-N2
latency was significantly longer in the older than in the younger par-
ticipants, but only in the control group.
It is generally agreed that older adults react more slowly than
younger adults, as demonstrated in a variety of cognitive tasks (Glisky,
2007; Salthouse, 2000). In fact, the slower RT in the older than in the
younger participants supports previous findings obtained with the AV
task in healthy subjects (Cid-Fernández, Lindín, & Díaz, 2016) and with
other tasks in healthy subjects (Lucci et al., 2013) and subjects with
aMCI (Ramos-Goicoa et al., 2016). However, the differences between
groups in this parameter are not always statistically significant (e.g.
Cid-Fernández et al., 2014b; Correa-Jaraba, Cid-Fernández, Lindín, &
Díaz, 2016).
Moreover, the older participants provided fewer correct responses
than the younger participants. Although a similar tendency was ob-
served in previous studies using the AV task, the differences was not
found to be statistically significant (Cid-Fernández et al., 2014b, 2016).
The discrepancy in the results of the different studies may be due to the
different age cut-off used here (69/70 years old in the present study;
64/65 years old in the previous studies). Besides, it seems that the
general increase in RTs across aging studies is usually associated with
little or no decrease in accuracy (Ratcliff, Thapar, & McKoon, 2010). In
addition, the control participants provided a greater number of correct
Table 2
Number of correct responses (Hits) and reaction times (RT, from the visual
stimulus onset to the button press), and amplitudes (in microvolts) and la-
tencies (in milliseconds, from the visual stimulus onset) for P3b and NoGo-P3
components for each age group.
YOUNGER (≤ 69 years old) OLDER (≥ 70 years old)
CONTROL aMCI CONTROL aMCI
Hits 224.2 (5.2) 215.5 (19.3) 210.1 (21.0) 200.3 (25.7)
RT 605.5 (86.7) 640.6 (64.4) 660.5 (107.3) 679.6 (96.2)
N2b Amp (Cz) −10.3 (7.0) −6.4 (4.6) −6.7 (9.2) −5.2 (4.8)
N2b Lat (Cz) 583.5 (49.1) 625.8 (33.2) 620.3 (60.8) 630.4 (65.7)
NoGo-N2 Amp (Cz) −8.0 (6.2) −4.1 (3.4) −4.7 (7.2) −3.6 (3.0)
NoGo-N2 Lat (Cz) 536.2 (22.7) 578.4 (51.4) 598.5 (58.9) 570.0 (64.2)
P3b Amp (Pz) 4.6 (7.4) 7.4 (5.9) 8.4 (9.1) 6.4 (5.7)
P3b Lat (Pz) 528.5 (80.4) 597.4 (87.9) 588.1 (111.1) 547.3 (108.1)
NoGo-P3 Amp (Cz) 10.8 (4.9) 11.0 (4.9) 10.4 (7.2) 11.0 (7.6)
NoGo-P3 Lat (Cz) 477.0 (74.4) 504.4 (53.5) 521.9 (77.2) 501.4 (97.2)
RT: reaction time; Amp: amplitude; Lat: latency.
S. Cid-Fernández et al. Biological Psychology 142 (2019) 108–115
112
responses than the aMCI participants, although the difference was only
marginally significant (0.07). This is consistent with the findings of a
previous study using the AV task (Cid-Fernández et al., 2014a), where
this result was significant.
Regarding the ERP parameters, the aMCI participants showed
longer Go-P3 and NoGo-N2 latencies than control participants, but only
those in the younger subgroup. This may indicate that the aMCI par-
ticipants aged 69 years or less old categorized the Go stimuli in the
working memory more slowly and were slower regarding early re-
sponse inhibition processing than their control counterparts. However,
this difference was not observed in the participants aged 70 years or
more. The latency values show that the evident (and significant) dif-
ference between the younger aMCI and control participants disappears
in the older subgroups (see Table 2 and Fig. 1).
These results may be able to explain at least in part the contra-
dictory results reported in other studies regarding Go/NoGo tasks per-
formed by aMCI participants. On one hand, López Zunini et al. (2016)
did not find any group differences between aMCI and control partici-
pants in the latencies of the NoGo-N2 and Go and NoGo-P3 ERP com-
ponents. The mean ages of their participants (control, mean age = 72.4
y-o; aMCI, mean age = 75.6 y-o) resemble the mean ages of our elderly
subgroup, so it is reasonable that they were not able to capture dif-
ferences in latencies between control and aMCI participants as those
observed in the present study in the younger age subgroup.
On the other hand, Mudar et al. (2016) found group differences in
N2 latency (globally, including both Go- and NoGo-N2), as this para-
meter was longer in the aMCI than in the control group. The mean ages
of their groups (control, mean age = 65.4 y-o; aMCI, mean age = 68.5
y-o) are much more alike our younger subgroup, so it is possible that
they were able to capture this global effect due to the age of their
sample (younger than in López Zunini et al., 2016). However, they did
not find differences in Go-P3 latency as those reported in this study, but
this might be explained by the different age range of the aMCI adults, as
in Mudar et al. (2016) it was slightly higher than in our study (our
study = 51 years-old onwards, their study = 57 years-old onwards).
The present results may reflect a decline in aMCI that becomes
evident early in aging (slower Go-P3 latency and slower NoGo-N2 la-
tency in younger aMCI relative to younger healthy adults), and in-
triguingly disappears in later aging stages (absence of differences in Go-
P3 and NoGo-N2 latencies between older aMCI relative to older healthy
adults). Although we are not able to infer the cause of this pattern from
this study, it might reflect a hypothetical compensatory mechanism that
would allow the aMCI patients to preserve their speed of stimulus ca-
tegorization after an early decline. Alternatively, this result might in-
dicate that those adults diagnosed with aMCI at an earlier age may
show larger impairments than those diagnosed later in aging. Any of
these hypotheses should be tested in future studies.
Ramos-Goicoa et al. (2016) also observed longer Go-P3 latencies in
middle-aged aMCI participants than in age-matched controls using a
Stroop task and a quite lower cut-off age (64/65 years old; age range of
the younger subgroups: 51–64 years old), indicating that regardless of
the cause of this effect it seems to be quite robust across tasks in rela-
tively young elderly. Hence, the age factor can mask some interesting
effects in the search for aMCI biomarkers, and might account for some
of the contradictory results in the literature regarding P3b and other
ERP components.
On the other hand, N2 amplitudes did not show any group differ-
ences, as in previous studies (López Zunini et al., 2016; Mudar et al.,
2016). Using the AV task, a previous study observed lower Go- and
NoGo-N2 amplitudes in aMCI than in control participants in the Stan-
dard Condition (standard auditory-visual stimuli pairs; Cid-Fernández
et al., 2014b), while another study did only observe differences be-
tween groups in this condition for Go-N2 amplitude as a marginally
significant effect (Cid-Fernández et al., 2017b). In the present study (see
Fig. 1 and Table 2), there is a tendency in line with the significant
results discussed throughout this article: it seems that Go- and NoGo-N2
amplitude might differ between groups (aMCI and controls) only in the
younger subgroup, and therefore might account for the apparently
contradictory results regarding these parameters in previous literature.
This hypothesis should be tested in future studies using larger samples,
where probably would reach significance.
Regarding the ROC curves, the Go-P3 latency, the NoGo-N2 latency
and the number of correct responses alone did not yield sensitivity and
specificity scores (equal or over 0.70) that would enable groups to be
distinguished. The same was true for the combination of the NoGo-N2
and Go-P3 latencies. However, the combination of the Go-P3 latency
and the number of hits may be useful for distinguishing aMCI from
control participants of age 69 years or less (sensitivity = 0.82 and
specificity = 0.75). Similar results were found for the combination of
the NoGo-N2 latency and the number of hits (sensitivity = 0.80 and
specificity = 0.75), and for the combination of the three parameters
(sensitivity = 0.70, specificity = 0.92).
Finally, it is worth noting that the results of the present study might
be restricted to cognitive control tasks. More ERP studies evaluating
these components, with other tasks and larger samples, would be ne-
cessary to draw more general conclusions about the modulations of age
in the search of aMCI biomarkers.
5. Conclusions
Task performance was worse in the older old participants ( > 70
years old) (longer RTs and less correct responses) than in the younger
old participants (50–69 years old). In addition, the aMCI participants
processed both the Go and the NoGo stimuli more slowly than the
control participants (longer NoGo-N2 and Go-P3 latencies in the
former), although only in the younger old subgroup.
In conclusion, aMCI was found to affect NoGo-N2 and Go-P3 la-
tencies in this study because modulation by the age factor on the group
effects was taken into account. Hence, it seems important to consider
this factor in future studies aiming to search for ERP biomarkers of
aMCI.
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